Vladislav Sandler - Hemogenyx Pharmaceuticals CEO CoFounder
| HOPHF Stock | USD 1.24 0.00 0.00% |
Insider
Vladislav Sandler is CEO CoFounder of Hemogenyx Pharmaceuticals Plc
| Phone | 44 79 0917 7311 |
| Web | https://www.hemogenyx.com |
Hemogenyx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1771) % which means that it has lost $0.1771 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3235) %, meaning that it generated substantial loss on money invested by shareholders. Hemogenyx Pharmaceuticals' management efficiency ratios could be used to measure how well Hemogenyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Lindquist | Celcuity LLC | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Erin JD | Shattuck Labs | 44 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Brian Sullivan | Celcuity LLC | 63 | |
| James Collins | Senti Biosciences | 58 | |
| Craig Esq | Cingulate | 51 | |
| Gail Farfel | ProMIS Neurosciences | 60 | |
| Larry MD | ProMIS Neurosciences | 75 | |
| Andrew MBA | Shattuck Labs | 40 | |
| MPH MD | Foghorn Therapeutics | 51 | |
| Peggy Scherle | Prelude Therapeutics | 63 | |
| Joseph Hazelton | Dyadic International | 49 | |
| Laurent Chardonnet | Prelude Therapeutics | 59 | |
| MD MBA | Shattuck Labs | 66 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Michael LaCascia | Foghorn Therapeutics | 59 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| Filip MD | Monte Rosa Therapeutics | 51 | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 |
Hemogenyx Pharmaceuticals Leadership Team
Elected by the shareholders, the Hemogenyx Pharmaceuticals' board of directors comprises two types of representatives: Hemogenyx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemogenyx. The board's role is to monitor Hemogenyx Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hemogenyx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemogenyx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladislav Sandler, CEO CoFounder | ||
| Alexis JD, Independent Director | ||
| Koen MD, Clinical Director | ||
| Andrew Wright, Financial Sec |
Hemogenyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hemogenyx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 8.17 M | |||
| Shares Outstanding | 1.14 B | |||
| Shares Owned By Insiders | 13.01 % | |||
| Price To Book | 1.78 X | |||
| EBITDA | (2.39 M) | |||
| Net Income | (5.1 M) | |||
| Cash And Equivalents | 6.84 M | |||
| Cash Per Share | 0.01 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Hemogenyx Pink Sheet
Hemogenyx Pharmaceuticals financial ratios help investors to determine whether Hemogenyx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemogenyx with respect to the benefits of owning Hemogenyx Pharmaceuticals security.